Lipum AB (OSTO:LIPUM) ROCE % : -341.60% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lipum AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lipum AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -341.60%.

Lipum AB ROCE % Historical Data

The historical data trend for Lipum AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB ROCE % Chart

Lipum AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-58.71

-194.75

-283.46

-125.21

-205.58

Lipum AB Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial										-347.74	-287.26	-109.40	-	-341.60

Lipum AB ROCE % Calculation

Lipum AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-37.047	/	( ( (34.551 - 4.843)	+	(12.11 - 5.777) )	/ 2 )
	=	-37.047	/	( (29.708	+	6.333)	/ 2 )
	=	-37.047	/	18.0205
	=	-205.58 %

Lipum AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-37.656	/	( ( (18.785 - 3.071)	+	(12.11 - 5.777) )	/ 2 )
	=	-37.656	/	( ( 15.714	+	6.333 )	/ 2 )
	=	-37.656	/	11.0235
	=	-341.60 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Lipum AB (OSTO:LIPUM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lipum AB ROCE % Related Terms

Thank you for viewing the detailed overview of Lipum AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipum AB (OSTO:LIPUM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tvistevagen 48 C, Umea, SWE, 907 36

Website

https://www.lipum.se

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB (OSTO:LIPUM) Headlines

No Headlines